semaglutide patent expiration 2031 & Tirzepatide Considerations What is the patent landscape

Get In Touch Why Researchers Choose Retatrutide Retatrutide is gaining attention for its multi-receptor activity in metabolic research, targeting GLP-1, GIP, and glucagon pathways with strong study potential

[2] [3] It belongs to a novel class of agents known as triple hormone receptor agonists , meaning it simultaneously activates three distinct receptors involved in appetite regulation and energy metabolism: GLP-1 (glucagon-like peptide-1) receptor reduces appetite and slows gastric emptying GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin secretion and, based on preclinical and early clinical evidence, may contribute to improved fat metabolism Glucagon receptor preclinical and early clinical data suggest activation of this receptor may increase energy expenditure and promote fat breakdown (lipolysis), though the precise contribution in humans is still being characterised This triple-action mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist)

If youre injecting a tirzepatide pen, skip ahead to step 6 after youve performed this step

Contraindications include: Uncontrolled hypertension (systolic 140 or diastolic 90 mmHg) Known cardiovascular disease Use within 6 months of myocardial infarction or stroke Concurrent naltrexone therapy For women aged 30, 49 who are using hormonal contraceptives, no dose adjustment of either bremelanotide or the contraceptive is required

Widespread within Sub-Saharan Africa but absent from semi-arid and arid regions